<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53842">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405221</url>
  </required_header>
  <id_info>
    <org_study_id>J1553</org_study_id>
    <secondary_id>IRB00054202</secondary_id>
    <nct_id>NCT02405221</nct_id>
  </id_info>
  <brief_title>Clinical Trial Safety and Feasibility of TA-CIN Vaccine in Combination With GPI-0100 Adjuvant in Patients With a History of HPV16 Associated Cervical Cancer</brief_title>
  <official_title>A Phase I Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine in Combination With GPI-0100 Adjuvant in Patients With a History of HPV16 Associated Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be looking at what dose of the TA-CIN/GPI-0100 vaccine is safe and effective
      in patients with a history of HPV16 associated cervical cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the rate of AEs, serious AEs, deaths and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HPV16 Associated Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>TA-CIN/GPI-0100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TA-CIN/GPI-0100</intervention_name>
    <description>TA-CIN/GPI-0100 every 4 weeks for a total of 3 doses. Three dose levels of TA-CIN/GPI-0100 are planned.</description>
    <arm_group_label>TA-CIN/GPI-0100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with HPV16 related stage IB1-IV cervical cancer who completed definitive
             treatment within 3 years

          2. Patients with no evidence of disease recurrence

          3. Age â‰¥ 18 years

          4. ECOG Performance Status of 0 to 1

          5. Adequate organ function as defined by study-specified laboratory tests

          6. Must use acceptable form of birth control through the study and for 28 days after
             final dose of study drug

          7. Signed informed consent form

          8. Willing and able to comply with study procedures

        Exclusion Criteria:

          1. Currently have or have history of certain study-specified heart, liver, kidney, lung,
             neurological, immune or other medical conditions

          2. Systemically active steroid use

          3. Prior HPV vaccination

          4. Had surgery, chemotherapy, or radiation therapy within 28 days prior to receiving
             study drug

          5. Another investigational product within 28 days prior to receiving study drug

          6. Active or chronic HIV, HBV, or HCV infection

          7. Pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amy Horne, RN, BSN, OCN</last_name>
    <phone>410-955-8804</phone>
    <email>jhccro@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Fader, MD</last_name>
    <phone>410-955-8804</phone>
    <email>jhccro@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Horne, RN, BSN, OCN</last_name>
      <phone>410-955-8804</phone>
      <email>jhccro@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Fader, MD</last_name>
      <phone>410-955-8804</phone>
      <email>jhccro@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 29, 2015</lastchanged_date>
  <firstreceived_date>March 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
